Purpose: The present study aims to describe the differences in the prevalence of EGFR mutation of lung adenocarcinoma between private and public healthcare institutions.
Introduction
Lung cancer is one of the most prevalent malignancy in the world and the leading death cause due to cancer [1, 2] .
The estimated number of new cases detected every year is 1.8 million, accounting for 12.9% of all malignancies diagnosed in 2012, with an annual mortality rate of 19 .4%, which translates to 1.59 million deaths according to worldwide statistics. The most prevalent rates (up to 58%) have been found in Europe, East Asia, and Sub-Saharan Africa [3] . In Mexico, the incidence of lung cancer ranges between 4.3-6.8/100,000 habitats in the latest epidemiological report, accounting for 11% of cancer-specific deaths [4, 5] . Notwithstanding that smoking is one of the most recognized risk factors for lung cancer (85% in men and 47% in women), different risk factors have been described, including exposure to wood smoke, work-related exposure (silica, carbon, radon, and petrochemical substances), among others [6, 7] .
The most common subtype of lung cancer is adenocarcinoma (40% in men and up to 50% in women), being especially prevalent in non-smokers with a high frequency of mutations in specific genes, such as EGFR, KRAS, ALK, and ROS1. These mutations can be present in up to 64% of patients with adenocarcinoma, having special importance for the use of targeted therapy [7, 8] . EGFR classically described as the most prevalent gene mutated in lung adenocarcinoma have different mutations of clinical relevance, for example, exon 19 deletions and L858R substitutions in exon 21 accounting 90-95% of the cases. Their frequency varies depending on several factors like smoking history (more prevalent in non-smokers), sex (more common in female patients) and race (10-15% in Caucasians and up to 50% in the Asian population) [9] . The differences mentioned above have been of utility for the introduction in the therapeutic approach of multiple agents approved in first-line, including Erlotinib, Gefitinib, and Afatinib [10] [11] [12] [13] [14] [15] . More recently, due to T790M tyrosine kinase inhibitors resistance mutation, a third-generation of inhibitors have been approved, with promising results [16] [17] [18] [19] [20] [21] . In Mexico, there are multiple disparities and Arch Clin Med Case Rep 2020; 4 (1): 97-105 DOI: 10.26502/acmcr.96550173
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limitations towards access to an adequate health system generating a great heterogeneity of population among those who attend a public and private institute. This exemplifies a common problem raised in developing countries where we need more investigation to improve the oncological approach.
The present study aims to describe the differences in the prevalence of EGFR mutation of lung adenocarcinoma between private and public healthcare institutions.
Material and Methods
This was a descriptive, observational, retrospective, multicenter study with a consecutive selection of 333 patients correlation was used to assess significance between quantitative variables with a criterion for statistical significance of p <0.05. One-factor Anova was used to determine between-group variability. All financial related issues were absorbed by the investigation group from the study.
Results
A total of 333 patients were included, distributed among the 3 healthcare centers: 57 patients in the ABC Medical 
Discussion
Results from many studies have suggested that there are biological, clinical, and pathological differences across populations diagnosed with lung cancer, and these differences are known to influence not only the prognosis but also the efficacy of cancer treatments. 
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reports in the Asian population, and to prior reports from other hospitals in our country [22] , however, frequency in private institutions shows a prevalence of EGFR mutations of 29%, which does not match what has been reported in our population but rather aligns with the frequency of presentation in some Anglo-Saxon countries and the rest of Western Europe. With these specific results, we could infer that there are population differences between institutions, due to differences in access to private healthcare in the overall population. While most of the population has access to a social security program, a small group also enjoys coverage in private institutions; this small part of the population usually involves first-or second-generation European immigrants (primarily from countries with linguistic similarities), although they are Mexican by birth, a small proportion reside in Mexico City for a number of reasons, such as work or personal reasons. These patients are very different from the large majority of our country's population, and this could explain why their mutation expression resembles that of their country of origin. The higher presentation of EGFR mutations the public healthcare institution must consider that this healthcare center acts as a reference center for lung cancer, increasing the probability of patients with an EGFR mutation.
Our findings regarding age at presentation and clinical stage are consistent with what has been reported worldwide;
however, a larger percentage of women was observed (58.8% vs. 41.2%), which is probably explained, because of lower exposure to smoking in Mexico and higher exposure to wood smoke, a factor higher association of EGFR mutations in prior studies [25] .
The lower exposure to smoke in Mexico is also an important factor to consider, as there is compelling data showing that mutations presenting in smokers are different somatic mutations in the non-smoking population, with TP53 (38%), EGFR (20%), KRAS (13%), NFE2L2 (6%), and PIK3CA (4%) mutations were more common among smokers, and EGFR (61%), TP53 (15%), KRAS (4%), and PI3KCA (2%) mutations being more common among non-smokers [6] . The incidence of TP53 and KRAS mutations increases with smoking, while EGFR mutations decrease [26] [27] [28] . Clinical stage IV was the most prevalent, as would be expected due to usually late diagnosis.
However, we found that most patients with clinical stage I-II were diagnosed in private hospitals, which can be due to better access to programmed follow-up tests or routine laboratory exams that help to detect anomalies earlier, leading to an earlier intervention.
Conclusion
While findings in terms of age, gender, and clinical presentation were similar to prior reports, we found that there is a statistically significant difference between the frequency of EGFR mutations between populations attending public and private healthcare institutions, probably related to ethnic differences between populations. The predominant population in private hospitals involves immigrants from Europe and the United States and their descendants in the analyzed population. Within what appears to be a single population, they are different factors (ethnicity, ancestral background, exposure to smoking, firewood smoke, prior infectious processes) that create differences within it. This explains why individual clinical characteristics are to be considered at all times, as they influence both the prognosis 
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